A Pilot Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs APX 005M (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- 16 Oct 2017 Status changed from not yet recruiting to recruiting.
- 28 Aug 2017 Planned initiation date changed from 21 Aug 2017 to 30 Sep 2017.
- 08 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 21 Aug 2017.